Skip to main content
. 2024 Sep 7;63(9):1301–1312. doi: 10.1007/s40262-024-01411-1

Table 1.

Parameter estimates of the pharmacodynamic model for asciminib 80 mg q.d. versus 40 mg b.i.d. in the subset of patients without the T315I mutation

Cmin (RSE) Regimen (RSE)
Population means
 Q (t = 0) 0.0260 (45.4%) 0.0156 (46.4%)
 P (t = 0) 0.0246 (4.9%) 0.0253 (4.0%)
 R (t = 0) 2.05 × 10–9 (75.4%) 8.94 × 10–6 (48.4%)
 kgr (1/y) 28 (fixed) 28 (fixed)
 kqp (1/y) 0.53 (fixed) 0.53 (fixed)
 kqr (1/y) 6.5 (fixed) 6.5 (fixed)
 Effmag 42.1 (3.4%) 39.8 (3.18%)
 Gamma 0.0399 (7.2%)
Standard deviation of random effects (IIV)
 Q (t = 0) 3.49 (7.6%) 3.72 (8.3%)
 P (t = 0) 0.147 (20.5%) 0.174 (17.2%)
 R (t = 0) 2.36 (27.4%) 3.37 (11.7%)
 Effmag 0.265 (7.1%) 0.277 (6.3%)
 Cov (Q [t = 0], Effmag) − 0.647 (11.1%) − 0.718 (7.1%)
Covariate effect magnitude††
 L10BA0 on Q (t = 0) 2.53 (14.7%) 1.97 (19.8%)
 L10BA0 on P (t = 0) 2.51 (1.7%) 2.55 (1.5%)
 Regimen on Effmag (80 mg q.d.) − 0.0447 (148%)
 NUMTTRT (3,4,5) on Effmag − 0.0725 (56.7%) − 0.0692 (55.4%)
Residual error
 a (additive) 0.23 (2.7%) 0.19 (2.6%)
 b (proportional) 0.0975 (7.1%) 0.081 (6.3%)
Fit statistics
 – 2 log-likelihood 1316.21 998.68
 Corrected BIC 1410.42 1090.72

BIC Bayesian information criteria, b.i.d. twice daily, Cmin minimum plasma concentration, Cov covariate, Effmag effect of drug, IIV inter-individual variability, kgr growth rate of resistant and proliferating cells, kqp and kqr transfer rate constants between proliferating, resistant and quiescent compartments, L10BA0 baseline log10-transformed BCR::ABL1IS, NUMTTRT number of prior TKI treatments, P proliferating leukemic bone marrow cells, Q quiescent stem cells, q.d. once daily, R proliferating resistant cells, RSE relative standard error, t time, TKI tyrosine kinase inhibitor, y year

This value is for the 40-mg b.i.d. dosing regimen

††Covariate effect magnitude is reported as log. The linear effect is exp(value)